Last Updated : July 24, 2024
Details
Program Updates
1. Working Toward Target Zero: Expanding Our Rolling Review Pilot Process
Canada’s Drug Agency is taking a new step to improve the timeliness of patient access to new drugs. The action supports our ambitious Target Zero campaign — an initiative that aims to achieve zero days between Health Canada’s regulatory approval of a drug and our reimbursement recommendation to participating public drug plans.
Last Updated : July 25, 2024
Details
Last Updated : July 24, 2024
Details
| Call for patient/clinician/industry input open | 11-Jul-24 |
|---|---|
| Call for patient/clinician/industry input closed | 30-Aug-24 |
| Submission received | 04-Jul-24 |
| Review initiated | 05-Jul-24 |
| Expert committee meeting (initial) | 21-Nov-24 |
| Draft recommendation posted for stakeholder feedback | 12-Dec-24 |
| End of feedback period | 03-Jan-25 |
| Final recommendation posted | 04-Feb-25 |
| CADTH review report(s) posted | 29-Jan-25 |
Last Updated : February 10, 2025
Details
| Call for patient/clinician input open | 04-Jul-24 |
|---|---|
| Call for patient/clinician input closed | 30-Aug-24 |
| Submission received | 15-Aug-24 |
| Submission accepted | 29-Aug-24 |
| Review initiated | 30-Aug-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 18-Nov-24 |
| Deadline for sponsors comments | 27-Nov-24 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 19-Dec-24 |
| Expert committee meeting (initial) | 08-Jan-25 |
| Draft recommendation issued to sponsor | 29-Apr-25 |
| Clarification: - pERC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements. . | |
| Draft recommendation posted for stakeholder feedback | 08-May-25 |
| End of feedback period | 23-May-25 |
Last Updated : April 30, 2025
Details
| Call for patient/clinician input open | 04-Jul-24 |
|---|---|
| Call for patient/clinician input closed | 23-Aug-24 |
| Submission received | 15-Aug-24 |
| Submission accepted | 29-Aug-24 |
| Review initiated | 30-Aug-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 28-Nov-24 |
| Deadline for sponsors comments | 09-Dec-24 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | 10-Jan-25 |
| Expert committee meeting (initial) | 22-Jan-25 |
| Draft recommendation issued to sponsor | 04-Feb-25 |
| Draft recommendation posted for stakeholder feedback | 13-Feb-25 |
| End of feedback period | 28-Feb-25 |
| Final recommendation issued to sponsor and drug plans | 12-Mar-25 |
| Final recommendation posted | 31-Mar-25 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 27-Mar-25 |
| CDA-AMC review report(s) posted | - |
Last Updated : April 28, 2025
Details
| Call for patient/clinician input open | July 03, 2024 |
|---|---|
| Call for patient/clinician input closed | August 23, 2024 |
| Submission received | August 14, 2024 |
| Submission accepted | August 28, 2024 |
| Review initiated | August 29, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | November 15, 2024 |
| Deadline for sponsors comments | November 26, 2024 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | December 19, 2024 |
| Expert committee meeting (initial) | January 08, 2025 |
| Draft recommendation issued to sponsor | January 21, 2025 |
| Draft recommendation posted for stakeholder feedback | January 30, 2025 |
| End of feedback period | February 13, 2025 |
| Final recommendation issued to sponsor and drug plans | February 28, 2025 |
| Final recommendation posted | March 19, 2025 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | March 17, 2025 |
| CDA-AMC review report(s) posted | - |
Last Updated : March 31, 2025
Details
| Submission received | 11-Jul-24 |
|---|---|
| Review initiated | 12-Jul-24 |
| Expert committee meeting (initial) | 21-Nov-24 |
| Draft recommendation posted for stakeholder feedback | 12-Dec-24 |
| End of feedback period | 03-Jan-25 |
| Final recommendation posted | 04-Feb-25 |
| CADTH review report(s) posted | 29-Jan-25 |
Last Updated : February 10, 2025
Details
| Submission received | 11-Jul-24 |
|---|---|
| Review initiated | 12-Jul-24 |
| Expert committee meeting (initial) | 21-Nov-24 |
| Draft recommendation posted for stakeholder feedback | 12-Dec-24 |
| End of feedback period | 03-Jan-25 |
| Final recommendation posted | 04-Feb-25 |
| CADTH review report(s) posted | 29-Jan-25 |
Last Updated : February 10, 2025
Details
Program Updates
1. Expanding Our Scientific Advice Services for Canada’s Life Sciences Sector
Canada’s Drug Agency is launching a new 1-year learning period in our Scientific Advice program that will expand the type of guidance we offer to drug manufacturers to include those that are seeking advice after a “do not reimburse” recommendation is made for their product.
Last Updated : June 27, 2024